NASDAQ:GEMP - Gemphire Therapeutics Stock Price, Forecast & News

Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."

Gemphire Therapeutics Inc (NASDAQ:GEMP) announced its earnings results on Friday, March, 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.15. View Gemphire Therapeutics' Earnings History.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemphire Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gemphire Therapeutics.

Media coverage about GEMP stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Gemphire Therapeutics earned a media sentiment score of -3.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Gemphire Therapeutics.

Some companies that are related to Gemphire Therapeutics include Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Phathom Pharmaceuticals (PHAT), Portola Pharmaceuticals (PTLA), Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA), Dermira (DERM), Myovant Sciences (MYOV), Gossamer Bio (GOSS), I-Mab (ARQT), Achillion Pharmaceuticals (ACHN), Applied Therapeutics (APLT), Radius Health (RDUS), Cytokinetics (CYTK) and Stoke Therapeutics (STOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include Anavex Life Sciences (AVXL), Progenics Pharmaceuticals (PGNX), Pixelworks (PXLW), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Nektar Therapeutics (NKTR), Protalix Biotherapeutics (PLX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO) and Melinta Therapeutics (MLNT).

(GEMP) raised $30 million in an IPO on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GEMP stock can currently be purchased for approximately $17.86.

Gemphire Therapeutics has a market capitalization of $265.58 million. Gemphire Therapeutics employs 9 workers across the globe.View Additional Information About Gemphire Therapeutics.

The official website for Gemphire Therapeutics is http://www.gemphire.com/.

Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]